QS Investors LLC grew its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 1.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,215 shares of the company’s stock after purchasing an additional 1,685 shares during the period. QS Investors LLC’s holdings in Eli Lilly and were worth $8,464,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Candriam Luxembourg S.C.A. boosted its stake in Eli Lilly and by 166.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock valued at $36,818,000 after buying an additional 269,038 shares in the last quarter. Chevy Chase Trust Holdings Inc. boosted its stake in Eli Lilly and by 1.0% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 851,985 shares of the company’s stock valued at $72,879,000 after buying an additional 8,328 shares in the last quarter. Exane Derivatives boosted its stake in Eli Lilly and by 2,838.2% during the fourth quarter. Exane Derivatives now owns 18,687 shares of the company’s stock valued at $1,578,000 after buying an additional 18,051 shares in the last quarter. BARING ASSET MANAGEMENT Ltd boosted its stake in Eli Lilly and by 114.6% during the third quarter. BARING ASSET MANAGEMENT Ltd now owns 43,492 shares of the company’s stock valued at $3,721,000 after buying an additional 23,229 shares in the last quarter. Finally, Bank of the Ozarks boosted its stake in Eli Lilly and by 18.0% during the third quarter. Bank of the Ozarks now owns 10,068 shares of the company’s stock valued at $861,000 after buying an additional 1,535 shares in the last quarter. 77.58% of the stock is currently owned by institutional investors.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 860 shares of Eli Lilly and stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total value of $65,790.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 212,261 shares of company stock worth $18,627,485. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Co (NYSE LLY) opened at $79.61 on Monday. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a one year low of $73.69 and a one year high of $89.09. The firm has a market capitalization of $87,220.55, a P/E ratio of 18.60, a P/E/G ratio of 1.48 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. During the same period last year, the business earned $0.95 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. research analysts predict that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
WARNING: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/12/eli-lilly-and-co-lly-shares-bought-by-qs-investors-llc.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.